Difference between revisions of "Increasing Willingness and/or Ability of Governments to Sponsor Biotech Research."
Line 4: | Line 4: | ||
==Enablers:== | ==Enablers:== | ||
• Biotech has been declared a core topic of the economic policy of many governments | • Biotech has been declared a core topic of the economic policy of many governments<br> | ||
• Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth | • Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth<br> | ||
• Lack of private venture capital in certain countries triggering calls for government sponsorship | • Lack of private venture capital in certain countries triggering calls for government sponsorship<br> | ||
• Worldwide diseases | • Worldwide diseases<br> | ||
• Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine | • Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine<br> | ||
• Few other alternatives for Research Sponsorship | • Few other alternatives for Research Sponsorship<br> | ||
==Inhibitors:== | ==Inhibitors:== |
Revision as of 13:09, 2 December 2005
Description:
Many governments are willing to support and sponsor fundamental research in biotech by massive funds, many have declared biotech a core issue in their economic strategy and many are trying to attract biotech companies to move production sites and research activities to the territory of their countries. A biotech company is almost always welcome.
Enablers:
• Biotech has been declared a core topic of the economic policy of many governments
• Governments perceive biotech industry as one possible panacea to solve economic problems and to trigger economic growth
• Lack of private venture capital in certain countries triggering calls for government sponsorship
• Worldwide diseases
• Desire to increase Standard of living by both, creation of high qualification jobs and availability of state of the art medicine
• Few other alternatives for Research Sponsorship
Inhibitors:
• Budgetary limitations • Exploding healthcare costs • Priorities other than biotech • Other promising opportunities for investment and sponsorship
Paradigms:
• Perception of biotechnology as a core topic for the competitiveness of a nation
Experts:
• Ernst & Young, biotech Report
Timing:
• 2000 – 2005 Biotech strategies by several countries • 2001: Healthcare Spending by US Goverment passes 20% of governmental budget • 2001: Lisbon Agenda; Strategic vision of EU for Biotech in Europe • 11/2002: First People suffering from SARS identified in Province of Guangdong, China • 2005: 124 cases of bird flu reported, 63 persons death since 2003; 150 million animals killed for reasons of precaution
Web Resources:
• WHO